Biologics, small molecules, steroids, biosimilars, approvals, and treatment access updates.
Page 6 of 26 · 1221 articles
Bright, round objects on stomach CT scans can be mistaken for retained pills or bleeding. For people with Crohn's disease who commonly receive CT enterography and may have bile reflux or duodenal narrowing, this report...
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ontunisertib.
IBD patients often have depression and anxiety that current anti-TNF biologics do not adequately treat. An engineered probiotic that both neutralizes local TNFα and promotes GABA-producing microbes could address...
This study suggests an existing antimalarial drug, artemisinin, may reduce inflammation and improve gut barrier function in a mouse model of ulcerative colitis by targeting CD40 — a pathway relevant to immune-driven gut...
A colon-targeted delivery system could allow an anti-inflammatory plant extract (Myrica esculenta) to reach the colon with minimal systemic exposure, which may be relevant for developing localized treatments for...
The report suggests an investigational, gut-restricted ALK5 inhibitor (ontunisertib) had sustained symptom control, high remission rates, and few procedures or surgeries in an open-label extension for fibrostenosing...
Cure8 could only read part of this source from rttnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ontunisertib.
Shortening ustekinumab dosing intervals raised drug levels and was associated with high rates of steroid-free clinical remission in this small prospective IBD cohort, offering a practical option for patients who lose...
If you have fibrostenosing Crohn’s disease, this investigational oral drug is being studied specifically for strictures — the company reports high CDAI remission in the extension and plans a larger randomized study...
This registry will collect real-world data on guselkumab use in adults with moderate-to-severe Crohn's disease or ulcerative colitis, focusing on how long patients stay on treatment, effectiveness in routine practice,...
Patients with fibrostenosing Crohn’s disease have limited treatment options for the fibrotic strictures that can lead to procedures and surgery. These OLE findings suggest ontunisertib may be safe long-term and could...
The article provides up-to-6-year safety data for ontamalimab in people with moderate-to-severe UC and CD, which helps patients and clinicians understand long-term tolerability of this investigational anti–MAdCAM-1...
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Ulcerative colitis, Inflammatory bowel disease, and Upadacitinib. The original article is from Clinical Gastroenterology and...
A single‑patient report suggests guselkumab (IL‑23 inhibitor) may control both refractory pyoderma gangrenosum and coexisting Crohn disease when several prior treatments failed.
This registry will gather real-world safety and effectiveness data on infliximab in Chinese children with moderate-to-severe Crohn's disease, which can help clinicians and families understand how the drug performs...
OTC painkiller use is very common among people with IBD, and those with recent disease activity are more likely to use them frequently and to take them specifically for IBD-related pain. Knowing this can help clinicians...
This case series points to risankizumab as a potential option for children with IBD who have failed multiple biologics, and it reports use of noninvasive monitoring like intestinal ultrasound.
This large real-world study found upadacitinib was associated with lower risk of treatment failure and more corticosteroid-free stability compared with several other advanced therapies for ulcerative colitis —...
The report highlights a serious drug-related complication (pancytopenia/myelosuppression and hair loss) in a patient treated with azathioprine plus sulfasalazine for ulcerative colitis, suggesting clinicians and patients...
Children with IBD and their caregivers may be interested in subcutaneous infliximab as an alternative to regular IV infusions because this review suggests it can maintain drug levels and remission after switching, with...
Hospitalized patients with acute severe ulcerative colitis often need rescue therapy to avoid colectomy.
This report describes combined use of upadacitinib and ustekinumab to treat severe, refractory perianal Crohn’s disease in an adolescent — a scenario many patients and caregivers find especially difficult to manage.
The trial suggests starting infliximab early can delay the need for further biologic escalation in children with moderate-to-severe Crohn’s disease, and that stopping anti‑TNF after induction often leads to relapse.
Researchers tested whether alpha-lipoic acid — an antioxidant with potential anti-inflammatory effects — can improve symptoms and quality of life when added to standard mesalamine treatment for mild-to-moderate...
Long-term real-world data on filgotinib help patients and clinicians understand how durable benefits and risks are over 2 years, including likelihood of staying on therapy and changes in inflammation markers.
The review suggests baseline corticosteroid use may change how well some advanced UC therapies work, especially IL-23 inhibitors and S1P modulators, which could affect treatment choices and trial reporting.
Mirikizumab showed higher rates of clinical and endoscopic remission than placebo in pooled randomized trials, which could expand treatment options for people with moderate-to-severe ulcerative colitis if confirmed by...
Cure8 could only read part of this source from American Journal of Therapeutics, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Infliximab, and Ustekinumab.
This study provides real-world data suggesting the oral α4-integrin antagonist carotegrast methyl can improve patient-reported stool frequency and rectal bleeding in many people with ulcerative colitis who did not...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Anti-TNF, and Medications. The original article is from Journal of gastrointestinal and liver diseases :...
Systemic glucocorticoids used for UC can cause bone loss; identifying early, noninvasive markers could let clinicians detect steroid-induced osteoporosis sooner and intervene to reduce fracture risk.
A PopPK model for subcutaneous infliximab could enable more personalized dosing when starting or switching patients to home-administered infliximab, potentially improving drug exposure and management for people with IBD.
Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...
If you or your clinician are considering switching from IV to subcutaneous vedolizumab, this multicentre cohort suggests most patients (about 84%) remain on the subcutaneous formulation at one year. The switch appears...
If you or your clinician are choosing between advanced therapies for ulcerative colitis, this study suggests past vedolizumab use may be linked to lower likelihood of responding to ustekinumab.
If validated, prealbumin — a routine blood protein test reflecting nutrition and inflammation — could help predict who with Crohn’s disease is more likely to need abdominal surgery or to have endoscopic recurrence after...
Patients with IBD who may need dupilumab for another immune condition could benefit from evidence about whether combining dupilumab with IBD biologics or advanced therapies changes infection or healthcare-utilization...
New Phase II trials test whether a gut-activated oral PDE4 inhibitor can treat moderate-to-severe ulcerative colitis and Crohn’s while avoiding systemic PDE4 tolerability issues; positive Phase II results could add a new...
This project targets epithelial repair — a mechanism not directly addressed by most current IBD drugs — and reports early human safety/tolerability data, so it could lead to a new oral therapy for inducing and...
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from Alimentary Pharmacology &...
The study shows pouchitis is a frequent postoperative problem in children after RPC‑IPAA and that many will still require advanced IBD medications, so surgery may not end medical therapy needs.
Antibiotics can substantially change gut microbes; for people with IBD those changes may affect inflammation and gut barrier function. The review summarizes microbiome-targeted strategies that patients and clinicians may...
People with IBD often need long-term advanced therapies. Cancer risk concerns commonly influence treatment choices—this review compiles current evidence to help patients and clinicians weigh risks when starting or...
Cure8 found this source from onlinelibrary.wiley.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Upadacitinib. Open the original article for the full...
This study compares first‑line vedolizumab versus TNF antagonist strategies in biologic‑naive ulcerative colitis patients over multiple years — information that could affect treatment choice and expectations about...
This trial tests several targeted therapies (including risankizumab) alone and in combination for adults with moderate to severe Crohn's disease, aiming to measure endoscopic remission and safety. Positive findings could...
People with IBD may be interested because the review highlights a class of dietary polyphenols that could influence inflammation and immune pathways involved in Crohn’s disease and ulcerative colitis. It summarizes...
People who have both IBD and type 2 diabetes are at increased cardiovascular risk; this study suggests GLP-1–based therapies may be associated with lower rates of several heart and thrombotic events in that group.
